Expert Opinion on Drug Metabolism & Toxicology  [ISSN 1742-5255]; [e-ISSN 1744-7607] is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles and original papers on all aspects of ADME-Tox.

Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development.

Expert Opinion on Drug Metabolism & Toxicology addresses the needs of scientists and managers in the pharmaceutical industry, pharmacologists, clinical toxicologists and related professionals.

The Editors welcome:

    Reviews covering:
    metabolic, pharmacokinetic and toxicological issues relating to specific drugs, drug-drug interactions, drug classes or their use in specific populations;
    issues relating to enzymes involved in the metabolism, disposition and excretion of drugs;
    techniques involved in the study of drug metabolism and toxicology;
    novel technologies for obtaining ADME-Tox data.
    Drug Evaluations reviewing the clinical, toxicological and pharmacokinetic data on a particular drug.

Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections:

Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results;

Article Highlights – an executive summary of the author’s most critical points.

Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees.

Reach an international clinical and medical audience alongside other key option leaders in your field by publishing with Expert Opinion on Drug Metabolism & Toxicology, part of the Expert Collection brand.

EDITORIAL BOARD
 
EDITOR-IN-CHIEF 
Luis G. Valerio Jr, Ph.D. : Washington, DC, USA
Luis G. Valerio, Jr., Ph.D., is currently a Toxicology Branch Chief at the U.S. Food and Drug Administration (FDA).  Dr. Valerio has a strong background in public health and is multi-faceted having served with increasing responsibilities at the FDA Center for Drug Evaluation and Research, Center for Food Safety and Applied Nutrition, and the Center for Tobacco Products; contributing in areas of review, risk/safety science, compliance and enforcement, and applied regulatory research. For over 10 years he has made significant contributions to the field of computational toxicology, providing foundations and creating pioneering in silico predictive models for expert decision-support. Prior to joining the FDA, he was Head of Toxicology and Translational Science at Verto Solutions, LLC, in Washington, DC.  Of notable significance, he was Scientific Director of the Flavor and Extract Manufacturers Association (FEMA) of the United States. At FEMA he ensured the safety of flavors for the industry.  He has also been an industrial consumer product safety toxicologist for several years. He received his Ph.D. in Pharmaceutical Science (1998) from the University of Colorado, and was a Gastroenterology Fellow at the University of Colorado School of Medicine where he focused on hepatic metabolism of xenobiotics and molecular mechanisms of toxicity.  He was a U.S. National Science Foundation International Research Postdoctoral Fellow at the Autonomous University of Barcelona, Spain where he studied the biochemistry of the alcohol dehydrogenase enzyme family.  He received his Bachelor of Arts in Environmental, Population, and Organismic Biology from the University of Colorado, at Boulder.  Valerio is internationally recognized and has strong experience in emerging and predictive technologies in toxicology, pharmacokinetics, regulatory toxicology, and in pharmaceutical product science. His research interests include predictive metabolism, computational modeling, and development of strategies and methods for risk analysis. He has been on the advisory board of Expert Opinion on Drug Metabolism and Toxicology since 2009 and has been Editor-in-Chief since 2011.
 
Editorial Board  
Marion Walter Anders  : University of Rochester Medical Centre, Rochester, NY, USA 
Mark Cronin: Liverpool John Moores University, Liverpool, UK 
Amílcar Falcão: University of Coimbra , Coimbra, Portugal 
Simone Ferrero: University of Genoa, Genoa, Italy. 
Gert Fricker: University of Heidelberg, Heidelberg, Germany 
Geert Mannens: Janssen Pharmaceuticals, Beerse, Belgium  
Olavi Pelkonen: University of Oulu, Oulu, Finland 
Mario Pellegatti: Retired GSK Director, Italy  
Godefridus J Peters: VU University Medical Center, Amsterdam, Netherlands  
Italo Poggesi: Janssen Pharmaceuticals, Italy  
Adrian Ray: Gilead Sciences Inc., Foster City, CA, USA  
Jim Riviere: Kansas State University, Manhattan, KS, USA  
André Scheen: University of Liège, Liège, Belgium  
Yoshiya Tanaka: University of Occupational & Environmental Health Japan, Kitakyushu, Japan
Brian Tomlinson:   Chinese University of Hong Kong, Hong Kong SAR  
Jack Uetrecht: University of Toronto, Toronto, Ontario, Canada  
Vasilis Vasiliou: Yale University, New Haven, CT, USA  
Thomas J Walsh: Cornell University, Ithaca, NY, USA  
Hong Wan: Shanghai  Hengrui  Pharmaceutical Co. Ltd, China